SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

“It is well established that all three medications are effective at lowering blood glucose, but only SGLT2 inhibitors and GLP-1 agonists have established additional benefits at reducing ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

Certain diabetes medications may have additional health benefits for older adults, scientists from the University of Glasgow ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.